IPP Bureau
Daiichi Sankyo commits US $1 million humanitarian aid to Ukraine
By IPP Bureau - March 11, 2022
The money will be donated to the United Nations Children’s Fund (UNICEF)
Amity awards Dr Azad Moopen Doctorate for Philanthropy
By IPP Bureau - March 11, 2022
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
Aurobindo Pharma trains its managers to be `future ready’
By IPP Bureau - March 11, 2022
Partners with GITAM University to train 27 employees through a 10-day HR module and make them future-ready
Emmes acquires Casimir, its fourth major acquisition
By IPP Bureau - March 11, 2022
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
By IPP Bureau - March 11, 2022
Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally
Cancer surgeons gather in Delhi to learn new cancer therapies
By IPP Bureau - March 11, 2022
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
Strides receives USFDA approval for Colchicine tablets
By IPP Bureau - March 11, 2022
Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout
USFDA approves Lupin’s Vigabatrin oral solution
By IPP Bureau - March 11, 2022
The product will be manufactured at Lupin’s facility in Goa, India
Medical devices production under PLI scheme gets off the ground
By IPP Bureau - March 10, 2022
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
Gufic Biosciences collaborates with Selvax for cancer treatment
By IPP Bureau - March 10, 2022
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
Non-invasive leadless pacemaker implanted in a 60-year-old at Fortis Hospital, Malar
By IPP Bureau - March 10, 2022
The medical team led by Dr. Babu Ezhumalai implanted the dual-chamber leadless pacemaker through a non-surgical procedure successfully
Everlife acquires Research Instruments to boost presence in life science and clinical diagnostics
By IPP Bureau - March 10, 2022
The RI investment comes on the back of three other recently completed transactions in Malaysia and Singapore in the last two months
Insilico Medicine and University of Zurich partner to find therapy for Cystinosis
By IPP Bureau - March 10, 2022
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Pfizer initiates Phase2/3 study of Paxlovid in pediatric participants
By IPP Bureau - March 10, 2022
Paxlovid is the first oral therapy specifically designed to combat Covid-19 to be evaluated in a pediatric clinical study
Non-hazardous viral inactivation medium for Covid-19 available in Europe
By IPP Bureau - March 10, 2022
Breakthrough formulation helps reduce the risk of exposure using a non-hazardous formulation and leakproof format during transport and processing
